The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

The following is a summary of “Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal transition and promote bladder cancer progression,” published in the April 2025 issue of BMC ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

Head of the Oncology Division (solid tumours) in IQWiG's Drug Assessment Department. The main decisive factor is the survival advantage for bladder cancer patients for whom cisplatin-based therapy is ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...

HC Wainwright issued their FY2029 EPS estimates for CG Oncology in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings ...

CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a ...

CG Oncology, Inc. reported net losses of $88.0 million and $48.6 million for the years ended December 31, 2024, and 2023, respectively. As of December 31, 2024, the company had an accumulated deficit ...

March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...